Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes

Leukemia

Volumn 20, Issue 6, 2006, Pages 1096-1102

  Mous, R ^a   Savage, P ^b,c   Remmerswaal, E B M ^a   van Lier, R A W ^a   Eldering, E ^a   van Oers, M H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Alexis Biotech Ltd   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

B CLL; CD20; CMV; HLA class I; Immunotherapy

Indexed keywords

CD20 ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL;

EID: 33744477614     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404185     Document Type: Article

References (31)

1. Gorgun G, Holderried TAW, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8T cells. J Clin Invest 2005; 115: 1797-1805.
2. Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: Evidence of immune dysregulation. Br J Haematol 2001; 112: 959-964.
3. Yellin MJ, Sinning J, Covey LR, Sherman W, Lee JJ, Glickmannir E et al. T-lymphocyte T-cell B-cell activating molecule Cd40-I molecules induce normal B-cells or chronic lymphocytic-leukemia B-cells to express Cd80 (B7/Bb-1) and enhance their costimulatory activity. J Immunol 1994; 153: 666-674.
4. Arditti FD, Aviner S, Dekel B, Krauthgamer R, Gan J, Nagler A et al. Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third-party CTLs. Blood 2005; 105: 3365-3371.
5. Hoogendoorn M, Wolbers JO, Smit WM, Schaafsma MR, Barge RMY, Willemze R et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: Implications for adoptive immunotherapy. Leukemia 2004; 7: 1278-1287.
6. Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Osterborg A et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18: 1810-1815.
7. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917-2924.
8. Mackus WJM, Frakking FNJ, Grummels A, Gamadia LE, de Bree GJ, Hamann D et al. Expansion of CMV-specific CD8+CD45RA+CD27(-) T cells in B-cell chronic lymphocytic leukemia. Blood 2003; 102: 1057-1063.
9. Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EBM, Surachno S, Weel JFL et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood 2001; 98: 754-761.
10. Heidema J, de Bree GJ, de Graaff PMA, van Maren WWC, Hoogerhout P, Out TA et al. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 2004; 85: 2365-2374.
11. Kater AP, Remmerswaal EBM, Nolte MA, Eldering E, van Oers MHJ, van Lier RAW. Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol 2004; 126: 512-516.
12. Schultz J, Lin YK, Sanderson J, Zuo YT, Stone D, Mallett R et al. A tetravalent single-chain antibody-streptavid in fusion protein for pretargeted lymphoma therapy. Cancer Res 2000; 60: 6663-6669.
13. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 294-317.
14. Lens SMA, Drillenburg P, den Drijver BFA, van Schijndel G, Pals ST, van Lier RAW et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 1999; 106: 491-503.
15. van Leeuwen EM, Gamadia LE, Baars PA, Renunerswaal EB, ten Berge IJ, van Lier RA. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8(+) T cells. J Immunol 2002; 169: 5838-5843.
16. Savage P, Cowburn P, Clayton A, Man S, McMichael A, Lemoine N et al. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. Br J Cancer 2002; 86: 1336-1342.
17. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by Apo-1/(Fas/Cd95). Nature 1995; 373: 438-441.
18. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T-cells by flow-cytometry. Blood 1995; 86: 1408-1419.
19. Bitmansour AD, Douek DC, Maino VC, Picker LJ. Direct ex vivo analysis of human CD4(+) memory T cell activation requirements at the single clonotype level. J Immunol 2002; 169: 1207-1218.
20. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001; 2: 300-306.
21. Savage P, Cowburn P, Clayton A, Man S, Lawson T, Ogg G et al. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice. Int J Cancer 2002; 98: 561-566.
22. Lev A, Noy R, Oved K, Novak H, Segal D, Walden P et al. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci USA 2004; 101: 9051-9056.
23. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004; 104: 227-236.
24. Stebbing J, Gazzard B, Patterson S, Bower M, Perumal D, Nelson M et al. Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8(+) lymphocytes: A new approach to therapeutic vaccination. Blood 2004; 103: 1791-1795.
25. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: An overview of signals,**** mechanisms and functions. J Leukocyte Biol 2004; 75: 163-189.
26. Ruddle NH. Tumor-necrosis-factor (TNF-alpha) and lymphotoxin (TNF-beta). Curr Opin Immunol 1992; 4: 327-332.
27. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13: 455-481.
28. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
29. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389.
30. Golay J, Manganini M, Facchinmi V, Gramigna R, Broady R, Borleri G et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88: 1002-1012.
31. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263-1270.